About Event
As Moderna, Merck, BioNTech, and Genentech prepare for high-stakes PCV readouts, the entire field is watching 2025 as a defining year for personalized immunotherapy. Drug developers like yourselves must now translate breakthrough science into clinically and commercially viable vaccine platforms.
That’s why the 2nd Annual Personalized Cancer Vaccines Summit returns to Boston this November - as the only strategic forum, dedicated end-to-end to overcoming the scientific, operational, and regulatory complexities of delivering safe, scalable, and effective personalized cancer vaccines.
From mRNA to peptide, viral vector, and dendritic cell platforms, this is your definitive forum to benchmark across modalities, unlock real-world progress, and forge the strategic partnerships needed to get personalized vaccines to patients - faster, smarter, and at scale.
This Year’s Agenda Is Designed To Answer the Field’s Most Urgent Questions:
• How do we define and validate tumor-specific targets that translate into durable clinical responses across indications?
• What does a manufacturable, scalable, and regulator-ready PCV platform actually look like in 2025?
• Can turnaround time, cost-per-patient, and QC complexity be reduced without compromising precision or safety?
• How are developers redesigning trials in the adjuvant setting, and what evidence will drive approval in low-burden populations?
• Where are immune monitoring, biomarker strategy, and patient selection truly moving the needle?
• What are regulators, payers, and investors actually looking for to back Phase III commitments?
Join 80+ global experts across translational research, manufacturing, clinical development, regulatory, and commercial strategy to shape the future of personalized cancer vaccines - together.